Pharmacokinetics and pharmacodynamic effect of cren
fluid beta-amyloid in patients with mild-to-moderate A

Alzheimer's Research and Therapy

12, 16

DOI: 10.1186/s13195-020-0580-2

Citation Report

#	Article	IF	Citations
1	Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimerâ€™s Disease Treated with Escalating Doses for up to 133ÂWeeks. Journal of Alzheimer's Disease, 2020, 76, 967-979.	1.2	36
2	Alzheimer Disease Clinical Trials Targeting Amyloid. Neurologist, 2021, 26, 52-61.	0.4	19
3	Machine Learning Attempts for Predicting Human Subcutaneous Bioavailability of Monoclonal Antibodies. Pharmaceutical Research, 2021, 38, 451-460.	1.7	16
4	Fluid Biomarkers in Clinical Trials for Alzheimerâ€™s Disease: Current and Future Application. Journal of Alzheimer's Disease, 2021, 81, 19-32.	1.2	3
5	Critical Appraisal of Amyloid Lowering Agents in AD. Current Neurology and Neuroscience Reports, 2021, 21, 39.	2.0	57
6	Safety, Tolerability, and Pharmacokinetics of Highâ€Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2021, 110, 1337-1348.	2.3	6
7	Proportion of Women and Reporting of Outcomes by Sex in Clinical Trials for Alzheimer Disease. JAMA Network Open, 2021, 4, e2124124.	2.8	30
8	Current druggable targets for therapeutic control of Alzheimer's disease. Contemporary Clinical Trials, 2021, 109, 106549.	0.8	21
9	Alzheimer's Disease: Many Failed Trials, So Where Do We Go from Here?. Journal of Investigative Medicine, 2020, 68, 1135-1140.	0.7	17
10	Past, present and future of therapeutic strategies against amyloid-Î² peptides in Alzheimerâ€™s disease: a systematic review. Ageing Research Reviews, 2021, 72, 101496.	5.0	131
11	Sulforaphane ameliorates amyloid-Î²-induced inflammatory injury by suppressing the PARP1/SIRT1 pathway in retinal pigment epithelial cells. Bioengineered, 2022, 13, 7079-7089.	1.4	8
12	Amyloid-beta peptide and tau protein crosstalk in Alzheimerâ€™s disease. Neural Regeneration Research, 2022, 17, 1666.	1.6	87
13	The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nature Reviews Drug Discovery, 2022, 21, 306-318.	21.5	273
14	Iron Dysregulation in Mitochondrial Dysfunction and Alzheimerâ€™s Disease. Antioxidants, 2022, 11, 692.	2.2	30
15	Targeted protein degraders march towards the clinic for neurodegenerative diseases. Ageing Research Reviews, 2022, 78, 101616.	5.0	19
16	Impact of Anti-amyloid-Î² Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimerâ€™s Disease: A Focus on Aducanumab and Lecanemab. Frontiers in Aging Neuroscience, 2022, 14, 870517.	1.7	91
17	Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers. Neurotherapeutics, 2022, 19, 209-227.	2.1	36
18	Shared pathophysiology: Understanding stroke and Alzheimerâ€™s disease. Clinical Neurology and Neurosurgery, 2022, 218, 107306.	0.6	9

#	Article	IF	Citations
19	Anti-Amyloid-Î² Immunotherapy: A Leading Novel Avenue for Alzheimer's Disease. Mini-Reviews in Medicinal Chemistry, 2022, 22, .	1.1	0
20	Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease. JAMA Neurology, 2022, 79, 758.	4.5	52
21	Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimerâ€™s Disease: Towards a Personalized Polypharmacology Patient-Centered Approach. International Journal of Molecular Sciences, 2022, 23, 9305.	1.8	13
22	The Immune System as a Therapeutic Target for Alzheimerâ€™s Disease. Life, 2022, 12, 1440.	1.1	6
23	Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease. JAMA Neurology, 2022, 79, 1113.	4.5	57
24	Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates. CPT: Pharmacometrics and Systems Pharmacology, 2023, 12, 62-73.	1.3	7
25	Roles of Histone Acetyltransferases and Deacetylases in the Retinal Development and Diseases. Molecular Neurobiology, 2023, 60, 2330-2354.	1.9	2
26	Targeting the Brain with Single-Domain Antibodies: Greater Potential Than Stated So Far?. International Journal of Molecular Sciences, 2023, 24, 2632.	1.8	5